biogen has been an 'uninvestable' stock for awhile, says mizuho's jared holz
Published 1 year ago • 1.5K plays • Length 5:09
Download video MP4
Download video MP3
Similar videos
-
4:31
blocking the horizon-amgen deal will be worse for pharma than for biotech, says mizuho's jared holz
-
7:05
upside for emergent bio if they can get mpox vaccine rollout right, says mizuho's jared holz
-
6:57
mizuho's jared holz on drug price negotiations: more difficult for industry to get better medicines
-
3:14
election noise may make pharmaceutical stocks 'untenable' for investors, says mizuho's jared holz
-
4:08
weight loss drug market is just beginning to take off, says mizuho's jared holz
-
3:09
schein: the broadening of the economy is healthy after two years of dominance by the magnificent 7.
-
5:47
zealand's obesity drug shouldn't disrupt novo nordisk-eli lilly leadership: mizuho's jared holz
-
6:21
novo nordisk falls after strong q1 results, mizuho's jared holz talks what's next for the company
-
4:13
mizuho's jared holz on finding opportunities in the biotech space
-
3:56
it doesn't seem like there's too much momentum for healthcare stocks, says mizuho's jared holz
-
5:47
drugs for obesity are a massive market, says mizuho's jared holz
-
5:13
obesity drug enthusiasm can continue in 2024: mizuho's jared holz
-
5:52
expectations for pfizer have been low, says mizuho's jared holz on weight-loss pill setback
-
5:12
structure therapeutics is a 'no-brainer takeout' target, says mizuho's jared holz
-
6:08
eli lilly's dtc obesity drug push 'not necessarily an industry game changer': mizuho's jared holz
-
4:25
people are 'scratching and clawing' for negative narrative around obesity drugs: mizuho's jared holz
-
3:25
mizuho's jared holz on novo nordisk: there's not much upside near-term
-
3:27
medical device companies 'clear beneficiary' following humana's warning, says mizuho's jared holz
-
7:35
eli lilly's zepbound single-dose vials will expand access to more patients: mizuho's jared holz
-
4:30
roche's alzheimer drug failing was a tailwind for a biogen rally, mizuho's salim syed
-
4:57
health care bucks sell-off as eli lilly soars: mizuho's jared holz on what's next for the group
-
7:09
a biotech self-correction is in store, says oppenheimer's jared holz
Clip.africa.com - Privacy-policy